Showing results (231-240 of 295) with videos related to

Sort By:
Pageof 30
The Journal of Biological Chemistry|December 19, 2018
Quantitative biophysical analysis defines key components modulating recruitment of the GTPase KRAS to the plasma membraneBindu Lakshman, Simon Messing, Eva M Schmid, et al.
Nature Structural & Molecular Biology|September 29, 2022
Structure of the SHOC2-MRAS-PP1C complex provides insights into RAF activation and Noonan syndromeDaniel A Bonsor, Patrick Alexander, Kelly Snead, et al.
Nature|November 2, 2017
Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibitionMatthew J Hangauer, Vasanthi S Viswanathan, Matthew J Ryan, et al.
The Journal of Investigative Dermatology|July 1, 2020
Cutaneous T-Cell Lymphoma PDX Drug Screening Platform Identifies Cooperation between Inhibitions of PI3Kα/δ and HDACChi-Heng Wu, Chen-Yen Yang, Linlin Wang, et al.
Cancer Discovery|August 8, 2014
Development of siRNA payloads to target KRAS-mutant cancerTina L Yuan, Christof Fellmann, Chih-Shia Lee, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 11, 2019
Second harmonic generation detection of Ras conformational changes and discovery of a small molecule binderElizabeth Donohue, Sina Khorsand, Gabriel Mercado, et al.
Nature Communications|January 10, 2026
Structure of SHOC2-KRAS-PP1C complex reveals RAS isoform-specific determinants and insights into targeting complex assembly by RAS inhibitorsDaniel A Bonsor, Lorenzo I Finci, Jacob R Potter, et al.
Cancer Cell|October 8, 2013
Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic targetLuika A Timmerman, Thomas Holton, Mariia Yuneva, et al.
Nature Communications|February 20, 2021
KRAS interaction with RAF1 RAS-binding domain and cysteine-rich domain provides insights into RAS-mediated RAF activationTimothy H Tran, Albert H Chan, Lucy C Young, et al.
Pageof 30